开云app官网登录入口网页版-官方正版

#招募#

108篇内容 | 2501人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1548572, encodeId=ff1c15485e29f, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, objectTitle=NANOBIOTIX与联拓生物宣布，用于评估NBTXR3治疗头颈癌的NANORAY-312 III期试验在亚洲完成首位患者招募, objectType=article, longId=738601, objectId=0e2de3860180, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e2de3860180, replyNumber=0, likeNumber=89, createdTime=2022-09-10, rootId=0, userName=ms1260584454294838, userId=038c14086626, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e2de3860180, moduleTitle=NANOBIOTIX与联拓生物宣布，用于评估NBTXR3治疗头颈癌的NANORAY-312 III期试验在亚洲完成首位患者招募, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0e2de3860180)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1548571, encodeId=502715485e14c, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, objectTitle=联拓生物完成Mavacamten用于治疗中国梗阻性肥厚型心肌病患者的EXPLORER-CN III期关键临床试验的患者招募, objectType=article, longId=735587, objectId=f431e3558751, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f431e3558751, replyNumber=0, likeNumber=107, createdTime=2022-08-12, rootId=0, userName=ms1260584454294838, userId=038c14086626, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f431e3558751, moduleTitle=联拓生物完成Mavacamten用于治疗中国梗阻性肥厚型心肌病患者的EXPLORER-CN III期关键临床试验的患者招募, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f431e3558751)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1548570, encodeId=8d0915485e057, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, objectTitle=肿瘤领域临床医生诊疗观念合理应用项目招募, objectType=article, longId=724067, objectId=dbf0e2406706, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbf0e2406706, replyNumber=0, likeNumber=61, createdTime=2022-04-13, rootId=0, userName=ms1260584454294838, userId=038c14086626, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbf0e2406706, moduleTitle=肿瘤领域临床医生诊疗观念合理应用项目招募, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=dbf0e2406706)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1548569, encodeId=1eb7154856955, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, objectTitle=上海新冠感染者累计近10000例！交大、复旦紧急招募医学生志愿者，奔赴抗疫一线, objectType=article, longId=301748, objectId=3d8b301e4816, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d8b301e4816, replyNumber=0, likeNumber=84, createdTime=2022-03-28, rootId=0, userName=ms1260584454294838, userId=038c14086626, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d8b301e4816, moduleTitle=上海新冠感染者累计近10000例！交大、复旦紧急招募医学生志愿者，奔赴抗疫一线, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3d8b301e4816)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1548568, encodeId=590e1548568bb, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, objectTitle=吉林大学第一医院重要声明：未在互联网发布有偿招募临床试验受试者广告, objectType=article, longId=300318, objectId=9ed530031814, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ed530031814, replyNumber=0, likeNumber=99, createdTime=2022-03-10, rootId=0, userName=ms1260584454294838, userId=038c14086626, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ed530031814, moduleTitle=吉林大学第一医院重要声明：未在互联网发布有偿招募临床试验受试者广告, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9ed530031814)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1548567, encodeId=2b3c154856eb4, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, objectTitle=【招募】甲状旁腺功能减退症患者临床试验信息分享, objectType=article, longId=293222, objectId=4a012932222a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a012932222a, replyNumber=0, likeNumber=87, createdTime=2022-01-02, rootId=0, userName=ms1260584454294838, userId=038c14086626, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a012932222a, moduleTitle=【招募】甲状旁腺功能减退症患者临床试验信息分享, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4a012932222a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1548566, encodeId=e930154856687, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, objectTitle=JAK抑制剂联合疗法FMX114治疗轻中度特应性皮炎，临床试验中招募了第一位患者, objectType=article, longId=218973, objectId=dbd52189e3d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbd52189e3d5, replyNumber=0, likeNumber=72, createdTime=2021-10-22, rootId=0, userName=ms1260584454294838, userId=038c14086626, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbd52189e3d5, moduleTitle=JAK抑制剂联合疗法FMX114治疗轻中度特应性皮炎，临床试验中招募了第一位患者, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=dbd52189e3d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1548565, encodeId=70f41548565d4, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, objectTitle=首批入营公布| HiMed-Biodesign医创营百特透析、重症专场持续招募中!, objectType=article, longId=217854, objectId=a57f21e85417, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a57f21e85417, replyNumber=0, likeNumber=85, createdTime=2021-09-30, rootId=0, userName=ms1260584454294838, userId=038c14086626, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a57f21e85417, moduleTitle=首批入营公布| HiMed-Biodesign医创营百特透析、重症专场持续招募中!, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a57f21e85417)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1548564, encodeId=54941548564f6, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, objectTitle=Alzheimer's & Dementia：EXERT试验招募经验：有氧运动如何影响患有失忆性轻度认知障碍的老年人？, objectType=article, longId=214885, objectId=125421488592, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=125421488592, replyNumber=0, likeNumber=94, createdTime=2021-07-28, rootId=0, userName=ms1260584454294838, userId=038c14086626, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=125421488592, moduleTitle=Alzheimer's & Dementia：EXERT试验招募经验：有氧运动如何影响患有失忆性轻度认知障碍的老年人？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=125421488592)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1548563, encodeId=d5ce1548563fd, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, objectTitle=福利 | 医美术后体验招募计划，快来报名！, objectType=article, longId=211313, objectId=b215211313e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b215211313e7, replyNumber=0, likeNumber=73, createdTime=2021-05-16, rootId=0, userName=ms1260584454294838, userId=038c14086626, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b215211313e7, moduleTitle=福利 | 医美术后体验招募计划，快来报名！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b215211313e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1548562, encodeId=f671154856253, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, objectTitle=梅斯长期招募稿件、科学审核人、公众号运营丨一起投入到改善医疗质量的事业中, objectType=article, longId=210379, objectId=b7052103e9e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7052103e9e5, replyNumber=0, likeNumber=98, createdTime=2021-04-25, rootId=0, userName=ms1260584454294838, userId=038c14086626, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7052103e9e5, moduleTitle=梅斯长期招募稿件、科学审核人、公众号运营丨一起投入到改善医疗质量的事业中, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b7052103e9e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1548561, encodeId=13711548561df, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, objectTitle=苹果公司招募机器学习科学家，积极布局疾病早期检测, objectType=article, longId=209539, objectId=6d1c20953953, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d1c20953953, replyNumber=0, likeNumber=77, createdTime=2021-04-05, rootId=0, userName=ms1260584454294838, userId=038c14086626, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d1c20953953, moduleTitle=苹果公司招募机器学习科学家，积极布局疾病早期检测, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6d1c20953953)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1548560, encodeId=ea0c1548560b5, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, objectTitle=COVID-19候选疫苗VLA2001已完成I / II期临床试验的患者招募, objectType=article, longId=206516, objectId=fdf420651685, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdf420651685, replyNumber=0, likeNumber=92, createdTime=2021-02-02, rootId=0, userName=ms1260584454294838, userId=038c14086626, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdf420651685, moduleTitle=COVID-19候选疫苗VLA2001已完成I / II期临床试验的患者招募, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fdf420651685)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1548559, encodeId=08f3154855941, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, objectTitle=Nat Commun：尼古丁通过招募N2嗜中性粒细胞促进乳腺癌的肺转移, objectType=article, longId=206386, objectId=192c206386ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=192c206386ae, replyNumber=0, likeNumber=87, createdTime=2021-01-30, rootId=0, userName=ms1260584454294838, userId=038c14086626, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=192c206386ae, moduleTitle=Nat Commun：尼古丁通过招募N2嗜中性粒细胞促进乳腺癌的肺转移, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=192c206386ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1548558, encodeId=fcdf1548558da, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, objectTitle=JAMA Network Open：社交媒体招募癌症患者？或许时机尚早, objectType=article, longId=205943, objectId=8166205943f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8166205943f4, replyNumber=0, likeNumber=88, createdTime=2021-01-22, rootId=0, userName=ms1260584454294838, userId=038c14086626, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8166205943f4, moduleTitle=JAMA Network Open：社交媒体招募癌症患者？或许时机尚早, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8166205943f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1548557, encodeId=3220154855e35, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, objectTitle=患者招募：Pamrevlumab或安慰剂联合吉西他滨/白蛋白紫杉醇（G/N）作为新辅助治疗用于局部晚期不可切除胰腺癌：一项III期、随机、双盲研究, objectType=article, longId=204949, objectId=3e49204949d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e49204949d8, replyNumber=0, likeNumber=82, createdTime=2020-12-30, rootId=0, userName=ms1260584454294838, userId=038c14086626, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e49204949d8, moduleTitle=患者招募：Pamrevlumab或安慰剂联合吉西他滨/白蛋白紫杉醇（G/N）作为新辅助治疗用于局部晚期不可切除胰腺癌：一项III期、随机、双盲研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3e49204949d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1548556, encodeId=078815485561d, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, objectTitle=患者招募：重组人源化抗PD-1单克隆抗体（HX008）联合化疗对比帕博利珠单抗联合化疗作为一线方案治疗晚期或转移性非鳞非小细胞肺癌（NSCLC）的II/III期临床研究, objectType=article, longId=204948, objectId=3cf1204948c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cf1204948c8, replyNumber=0, likeNumber=82, createdTime=2020-12-30, rootId=0, userName=ms1260584454294838, userId=038c14086626, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cf1204948c8, moduleTitle=患者招募：重组人源化抗PD-1单克隆抗体（HX008）联合化疗对比帕博利珠单抗联合化疗作为一线方案治疗晚期或转移性非鳞非小细胞肺癌（NSCLC）的II/III期临床研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3cf1204948c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1548555, encodeId=6b6315485553d, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, objectTitle=患者招募：卡瑞利珠单抗联合法米替尼或安慰剂与化疗治疗非小细胞肺癌患者的随机、双盲、对照、多中心临床研究, objectType=article, longId=204834, objectId=996020483414, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=996020483414, replyNumber=0, likeNumber=99, createdTime=2020-12-25, rootId=0, userName=ms1260584454294838, userId=038c14086626, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=996020483414, moduleTitle=患者招募：卡瑞利珠单抗联合法米替尼或安慰剂与化疗治疗非小细胞肺癌患者的随机、双盲、对照、多中心临床研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=996020483414)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1548554, encodeId=0c1b154855479, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, objectTitle=患者招募：吡咯替尼联合沙利度胺治疗HER2突变型非小细胞肺癌的单臂、开放、前瞻性II期临床研究, objectType=article, longId=204833, objectId=e12e20483351, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e12e20483351, replyNumber=0, likeNumber=89, createdTime=2020-12-25, rootId=0, userName=ms1260584454294838, userId=038c14086626, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e12e20483351, moduleTitle=患者招募：吡咯替尼联合沙利度胺治疗HER2突变型非小细胞肺癌的单臂、开放、前瞻性II期临床研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e12e20483351)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1548553, encodeId=9b6d154855311, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, objectTitle=阿斯利康新冠疫苗计划在全球招募5万名志愿者，美国III期临床开启, objectType=article, longId=200167, objectId=7b7b20016e1e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b7b20016e1e, replyNumber=0, likeNumber=89, createdTime=2020-09-04, rootId=0, userName=ms1260584454294838, userId=038c14086626, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b7b20016e1e, moduleTitle=阿斯利康新冠疫苗计划在全球招募5万名志愿者，美国III期临床开启, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7b7b20016e1e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

招募

2020-05-29

ms1260584454294838 (审核中...)

前往app查看评论内容

#招募#

NANOBIOTIX与联拓生物宣布，用于评估NBTXR3治疗头颈癌的NANORAY-312 III期试验在亚洲完成首位患者招募

2022-09-10

ms1260584454294838 (审核中...)

前往app查看评论内容

#招募#

联拓生物完成Mavacamten用于治疗中国梗阻性肥厚型心肌病患者的EXPLORER-CN III期关键临床试验的患者招募

2022-08-12

ms1260584454294838 (审核中...)

前往app查看评论内容

#招募#

肿瘤领域临床医生诊疗观念合理应用项目招募

2022-04-13

ms1260584454294838 (审核中...)

前往app查看评论内容

#招募#

上海新冠感染者累计近10000例！交大、复旦紧急招募医学生志愿者，奔赴抗疫一线

2022-03-28

ms1260584454294838 (审核中...)

前往app查看评论内容

#招募#

吉林大学第一医院重要声明：未在互联网发布有偿招募临床试验受试者广告

2022-03-10

ms1260584454294838 (审核中...)

前往app查看评论内容

#招募#

【招募】甲状旁腺功能减退症患者临床试验信息分享

2022-01-02

ms1260584454294838 (审核中...)

前往app查看评论内容

#招募#

JAK抑制剂联合疗法FMX114治疗轻中度特应性皮炎，临床试验中招募了第一位患者

2021-10-22

ms1260584454294838 (审核中...)

前往app查看评论内容

#招募#

首批入营公布| HiMed-Biodesign医创营百特透析、重症专场持续招募中!

2021-09-30

ms1260584454294838 (审核中...)

前往app查看评论内容

#招募#

Alzheimer's & Dementia：EXERT试验招募经验：有氧运动如何影响患有失忆性轻度认知障碍的老年人？

2021-07-28

ms1260584454294838 (审核中...)

前往app查看评论内容

#招募#

福利 | 医美术后体验招募计划，快来报名！

2021-05-16

ms1260584454294838 (审核中...)

前往app查看评论内容

#招募#

梅斯长期招募稿件、科学审核人、公众号运营丨一起投入到改善医疗质量的事业中

2021-04-25

ms1260584454294838 (审核中...)

前往app查看评论内容

#招募#

苹果公司招募机器学习科学家，积极布局疾病早期检测

2021-04-05

ms1260584454294838 (审核中...)

前往app查看评论内容

#招募#

COVID-19候选疫苗VLA2001已完成I / II期临床试验的患者招募

2021-02-02

ms1260584454294838 (审核中...)

前往app查看评论内容

#招募#

Nat Commun：尼古丁通过招募N2嗜中性粒细胞促进乳腺癌的肺转移

2021-01-30

ms1260584454294838 (审核中...)

前往app查看评论内容

#招募#

JAMA Network Open：社交媒体招募癌症患者？或许时机尚早

2021-01-22

ms1260584454294838 (审核中...)

前往app查看评论内容

#招募#

患者招募：Pamrevlumab或安慰剂联合吉西他滨/白蛋白紫杉醇（G/N）作为新辅助治疗用于局部晚期不可切除胰腺癌：一项III期、随机、双盲研究

2020-12-30

ms1260584454294838 (审核中...)

前往app查看评论内容

#招募#

患者招募：重组人源化抗PD-1单克隆抗体（HX008）联合化疗对比帕博利珠单抗联合化疗作为一线方案治疗晚期或转移性非鳞非小细胞肺癌（NSCLC）的II/III期临床研究

2020-12-30

ms1260584454294838 (审核中...)

前往app查看评论内容

#招募#

患者招募：卡瑞利珠单抗联合法米替尼或安慰剂与化疗治疗非小细胞肺癌患者的随机、双盲、对照、多中心临床研究

2020-12-25

ms1260584454294838 (审核中...)

前往app查看评论内容

#招募#

患者招募：吡咯替尼联合沙利度胺治疗HER2突变型非小细胞肺癌的单臂、开放、前瞻性II期临床研究

2020-12-25

ms1260584454294838 (审核中...)

前往app查看评论内容

#招募#

阿斯利康新冠疫苗计划在全球招募5万名志愿者，美国III期临床开启

2020-09-04

科室
- - 订阅+
  - 更多科室
工具
服务